Despite being highly preventable, cervical cancer is the fourth most common cancer and
cause of cancer death in women globally. In low‐income countries, cervical cancer is often …

Primary care providers are uniquely poised to prevent, screen, and diagnose cervical
cancer. What started with the Papanicalaou smear in the 1940s, 1 has evolved into multiple …

Cervical cancer is the fourth most common cancer worldwide, with over 600,000 new cases
annually and approximately 350,000 cancer-related deaths per year. The disease burden is …

Importance High-risk human papillomavirus (hrHPV) is recognized as an etiologic agent for
cervical cancer, and hrHPV DNA testing is recommended as the preferred method of …

Primary human papillomavirus (HPV) testing, in which a high-risk HPV test is administered
without cytology, was first included in 2018 US cervical cancer screening guidelines …

Purpose: Unsatisfactory collection of cells during Papanicolaou (Pap) tests prevents the
detection of cervical cancer and dysplasia. Prior research found that trans masculine (TM) …

Introduction High‐risk human papilloma virus (hrHPV) DNA testing is more sensitive than
cytology screening, achieving greater protection against cervical cancer. Controversy exists …

Introduction: Cervical cancer (CC) is the third most common cancer in the world, and
Romania has the highest incidence of cervical cancer in Europe. The aim of this study was …

Background High-risk human papillomavirus (hrHPV) infection is a necessary cause of
almost all cervical cancers. Relative to hrHPV 16/18 infection, non-16/18 hrHPV infection is …

Abstract Background In the United States (US), racially minoritized people have higher rates
of cervical cancer morbidity and mortality compared to white individuals as a result of …